3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
30
Leukemia, B-Cell
10
Lymphoma
9
Leukemia
8
Recurrence
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Follicular
7
Neoplasms
6
Lymphoma, Mantle-Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Waldenstrom Macroglobulinemia
3
Burkitt Lymphoma
3
Lymphoma, B-Cell, Marginal Zone
2
Bronchiolitis Obliterans Syndrome
2
Thrombocytopenia
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Lymphoma, B-Cell
1
Lymphocytosis
1
Lymphadenopathy
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphoid
1
Fever
1
Fatigue
1
Agammaglobulinemia
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Oncology Patients Receiving Chemotherapy
×
ofatumumab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts